Georg Boonen – CEO, Max Zeller
Marking 160 years of uninterrupted evolution, Max Zeller stands at the intersection of tradition and modernity in plant-based healthcare. CEO Georg Boonen reflects on the company’s continued role in shaping…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Marking 160 years of uninterrupted evolution, Max Zeller stands at the intersection of tradition and modernity in plant-based healthcare. CEO Georg Boonen reflects on the company’s continued role in shaping…
Alexander Salzmann with nearly a decade at Sandoz, reflects on the company’s transition from a Novartis division to an independent, Swiss-listed entity. In this interview, Salzmann discusses the challenges and…
From regenerating damaged muscles to rewriting the cell manufacturing playbook, Switzerland’s next wave of biotech innovators is turning regenerative medicine into a precision science. Once considered futuristic, technologies like autologous…
Currently supplying high-quality medicines to approximately 1 billion patients around the world annually, few pharmaceutical companies straddle both scale and innovation as deliberately as Viatris. In Switzerland – a market…
Stefan Schmidt traces a dynamic career from early biotech ventures in Germany to senior leadership roles at AstraZeneca, Lonza, and now CEO of evitria, a specialised Swiss CRO focused on…
Luc Henry, co-founder and CEO of Limula, speaks about the challenges and opportunities in the field of cell and gene therapy. A chemist by training, Henry’s path from molecular sciences…
Thomas Bohn has led the Greater Geneva Bern area (GGBa) investment agency for over a decade, shaping Switzerland’s strategy to attract global life sciences firms. He focuses on quality over…
Daniel Palmacci, Head of Specialized Modalities at Lonza, combines entrepreneurial vision with deep technical expertise in advanced therapeutics manufacturing. With experience spanning chemical engineering, international operations, and biotechnology development across…
Neurim Pharmaceuticals is a research-driven pharmaceutical company dedicated to advancing science in central nervous system disorders, with a strong emphasis on sleep-related conditions. Carolin Hillebrand, Country Manager of Switzerland and…
Founded in 1971, the Helmut Horten Foundation has steadily evolved from a discreet philanthropic entity into a pivotal force within Switzerland’s medical research landscape. Today, under the leadership of Alain…
Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in…
Antoine Geissbühler wears many hats—physician, academic, innovator, and institutional leader—and is at the forefront of digital transformation in healthcare. In this wide-ranging conversation, the Dean of the Faculty of Medicine…
See our Cookie Privacy Policy Here
